SNBIF Stock Price, Chart, Stats & News

SanBio Company Limited is a biopharmaceutical firm specializing in the development, manufacture, and commercialization of regenerative cell therapies, with a primary focus on disorders of the central nervous system. A significant product in its portfolio is SB623, which has successfully completed Phase 2 clinical trials in both the United States and Japan for the treatment of traumatic brain injury (TBI). The company's research pipeline also explores the potential of SB623 for a variety of other conditions, including ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, and Alzheimer's disease, among others.